Abstract 782P
Background
CRS after neoadjuvant chemotherapy (NACT) and gBRCA status predict survival outcomes of women diagnosed with advanced HGSOC. We investigated the correlation between CRS and gBRCA to understand the potential of CRS as an inexpensive biomarker for PARPi therapy.
Methods
Analysis of the OC gBRCA testing database from a tertiary referral centre. Eligible criteria included women with FIGO stage IIIC/IV HGSOC who received NACT and had gBRCA tested between 01/09/2017 and 31/12/2022. Univariable and Multivariable (MV) Cox Proportional-Hazards Models were applied to assess the association between PFS, OS and clinical factors. Two-Proportions Z Test was applied to assess the proportions of CRS1+2 or CRS3 between gBRCA.
Results
536 women were eligible. Mean age 66 years (range 36–89). 139 had FIGO stage IVB HGSOC. 71% received 3-weekly carboplatin with paclitaxel. Median PFS was 14.4 months (95%CI 13.6–15.4) and OS 38.0 months (95%CI 34.8–42.6) in the overall population. Performance status (0–1 vs. 2–4), cytoreductive surgery (Yes vs. No) and gBRCA status (mutant[MT] vs. wild type[WT]) were predictive (PFS) and prognostic (OS) in the overall population (all P<0.05). 363 women underwent delayed primary surgery (DPS) and had a CRS. Of these, 90% received 3–4 cycles of NACT and 96% had optimal (≤1 cm) cytoreduction. In the NACT-DPS group, MV analysis showed that residual disease (≤1 vs. >1 cm), CRS (3 vs. 1+2) and gBRCA status (MT vs. WT) were predictive (PFS) (all P≤0.02). Proportion testing showed women with gBRCA2 were more likely to have CRS3 vs. CRS1+2 than those with gBRCA1 (P=0.008). Women with gBRCA1 (P=0.075) and gBRCA2 (P=0.078) were not more likely to have CRS3 vs. CRS1+2 then those with WT.
Conclusions
We found a correlation between CRS3 and gBRCA2, but not gBRCA1, in women with FIGO stage IIIC/IV HGSOC treated with NACT-DPS. CRS should be evaluated in a prospective study as a predictor of PARPi efficacy.
Table: 782P
CRS | gBRCA1 | gBRCA2 | WT | PFS, months (95%CI) |
1 | 7 | 1 | 60 | 12.1 (11.5–15.7) |
2 | 19 | 9 | 146 | 15.4 (14.4–16.7) |
1+2 | 26 (84%) | 10 (45%) | 206 (66%) | 14.9 (14.0–16.0) |
3 | 5 (16%) | 12 (55%) | 104 (34%) | 22.8 (20.7–27.9) |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R.D. Morgan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
800P - Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients
Presenter: Sarah Howlett
Session: Poster session 11
802P - Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study
Presenter: Frederik Marmé
Session: Poster session 11
803P - Pre-treatment systemic inflammatory markers predict survival in endometrial cancer cases: A Japanese gynaecologic oncology group 2043 exploratory data analysis
Presenter: Shin Nishio
Session: Poster session 11
805P - Tumor-informed ctDNA detection as a predictive marker for postoperative residual disease in epithelial ovarian cancer: A feasibility study
Presenter: Christoph Grimm
Session: Poster session 11
806P - Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers
Presenter: Ainhoa Madariaga Urrutia
Session: Poster session 11
807P - Predicting surgical outcomes in patients with advanced ovarian cancer through MRI based preoperative evaluation
Presenter: Shujuan Liu
Session: Poster session 11
808P - Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for monitoring treatment response and for detecting relapse in locally advanced cervical cancer
Presenter: Lars Sivars
Session: Poster session 11
809P - Mental and socioeconomic burden in endometrial and cervical cancer patients: A Swedish population-based study of survivorship
Presenter: jiangrong wang
Session: Poster session 11
810P - The influence of preoperative conization (pc) to patient’s (pts) outcome and tumor biology of cervical cancer (CC)
Presenter: Dimitra Trantaki
Session: Poster session 11
811P - Epidemiological landscape of cervical cancer in Latin America: EVITA LATAM (LACOG 0820)
Presenter: Graziela Zibetti Dal Molin
Session: Poster session 11